FIELD: organic and medicinal chemistry, oncology.
SUBSTANCE: invention relates to the field of radiopharmaceuticals intended for use as theranostic agents for the diagnosis and therapy of prostate cancer. The technical result of the claimed invention is to expand the arsenal of theranostic agents for selective targeting and penetration into pathogenic tumor tissues expressing PSMA, while simultaneously providing excellent cellular uptake and internalization characteristics at relatively low conjugate concentrations. The technical result is achieved by a PSMA-targeted compound to obtain a radionuclide-labeled complex intended for theranostics of tumors expressing PSMA, with the general formula Glu-Urea-Lys-2-naphthyl-L-alanine-L-tyrosine-8Aoc-Lys-DOTA-acetamide. The complex for theranostics of tumors expressing PSMA includes a PSMA-targeting compound with a radionuclide label, which is the radionuclide 177Lu.
EFFECT: obtaining PSMA-target compound and its complex with radionuclides for theranostics of tumor expressing PSMA.
2 cl, 8 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF OBTAINING PSMA-TARGET COMPOUND COMPLEX BASED ON UREA Lu-PS-161 AND COMPLEX | 2023 |
|
RU2808636C1 |
| LYOPHILISATE BASED ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS FOR PREPARING A RADIOPHARMACEUTICAL COMPOSITION IN FORM OF SOLUTION FOR INJECTIONS FOR TREATING PROSTATE CANCER, RADIOPHARMACEUTICAL COMPOSITION BASED ON IT FOR TREATING PROSTATE CANCER AND METHOD FOR PREPARING RADIOPHARMACEUTICAL COMPOSITION | 2023 |
|
RU2817970C1 |
| COMPLEX OF UREA DERIVATIVE WITH Tc RADIONUCLIDE LABEL FOR DIAGNOSIS OF TUMORS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, AND METHOD FOR PRODUCTION THEREOF | 2023 |
|
RU2825402C1 |
| COMPOUND FOR DIAGNOSING TUMOURS EXPRESSING PSMA AND COMPOSITION BASED THEREON | 2019 |
|
RU2730507C1 |
| NEW PSA-BINDING AGENTS AND THEIR USE | 2018 |
|
RU2787105C2 |
| COMPLEX CONTAINING A PSMA-TARGETING COMPOUND BOUND TO A LEAD OR THORIUM RADIONUCLIDE | 2018 |
|
RU2795398C2 |
| PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | 2018 |
|
RU2807076C2 |
| COMPOUND AND ITS COMPLEX WITH RADIONUCLIDE Lu FOR THERANOSTICS OF TUMORS EXPRESSING ON HER2 RECEPTORS | 2023 |
|
RU2826247C1 |
| RADIOPHARMACEUTICAL FOR THE DIAGNOSIS OF PROSTATE CANCER BY POSITRON EMISSION TOMOGRAPHY AND METHOD FOR ITS PRODUCTION | 2022 |
|
RU2796106C1 |
| RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS AND THEIR USE | 2018 |
|
RU2804297C2 |
